H.C. Wainwright lowered the firm’s price target on ALX Oncology (ALXO) to $5 from $25 and keeps a Buy rating on the shares after the company reported final data from the Phase 2 ASPEN-06 study.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

ALX Oncology (ALXO) Holdings announced the appointment of Harish Shantharam, CFA, as Chief Financial Officer, CFO. In addition, the company appointed Barbara Klencke, M.D., and Chris H. Takimoto ...

Of course, some criticize these modern logos as being copy-and-paste, minimalist and unoriginal. Those yearn to return to the unique logos of the 1990s and early 2000s, where the NFL used elements ...

ALX Oncology stock opened at $1.74 on Friday. The stock has a market capitalization of $91.77 million, a P/E ratio of -0.58 and a beta of 0.98. The company’s fifty day moving average price is $1 ...